Open an account

Kaya Holdings

KAYS · OTC

$0.0013−$0.0013 (−50.00%)TodayMarket closed ·
No price history for this range.

About KAYS

Kaya Holdings, Inc. is a legal marijuana enterprise, which engages in the production, distribution, and selling of cannabis products. The company is headquartered in Fort Lauderdale, Florida and currently employs 2 full-time employees. The company went IPO on 2003-06-02. The firm produces, distributes, and/or sells a full range of cannabis products including flowers, oils, vape cartridges and cannabis-infused confections, baked goods and beverages through a fully integrated group of subsidiaries supporting highly distinctive brands. The Kaya family of brands include Kaya Farms Cannabis and Kaya Buddie Strain Specific Cannabis Cigarettes. The Company’s subsidiaries include Kaya Brand International, Inc. (KBI) and Fifth Dimension Therapeutics, Inc. (FDT). FDT provides psychedelic mindcare treatments for veterans suffering from post-traumatic stress disorder (PTSD), addicts seeking to break addiction, individuals with eating disorders, and others with an array of treatment resistant mental health disorders.

Employees
2
Headquarters
FORT LAUDERDALE, Florida
Listed
Jun 2, 2003
Sector
Health Care
Industry
Pharmaceuticals
Website
kayaholdings.com

KAYS key statistics

Market cap
892.37K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.61K
Volume
9
Open price
$0.0013
High today
$0.0013
Low today
$0.0013
52 Week high
$0.0599
52 Week low
$0.0001

Kaya Holdings (KAYS) at a glance

As of Oct 9, 2026, Kaya Holdings (KAYS) shares are priced at $0.0013, giving the company a market cap of 892.37K and a price-to-earnings ratio of 0.00.

Volume so far is 9 shares, below the average of 9.61K shares a day.

Over the past year Kaya Holdings has ranged from $0.0001 to $0.0599, and now sits 2% of the way up that range.

Kaya Holdings met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q3 FY25 it reported -$0.06 per share against an estimate of $0.00.

KAYS earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 3 quarters.

  1. Q2 FY23: reported -$0.03 per share against an estimate of $0.00
  2. Q3 FY23: reported $0.00 per share against an estimate of $0.00
  3. Q3 FY25: reported -$0.06 per share against an estimate of $0.00

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.